Literature DB >> 34815553

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.

Nobuharu Tamaki1,2, Veeral Ajmera1, Rohit Loomba3,4.   

Abstract

Hepatic steatosis is a key histological feature of nonalcoholic fatty liver disease (NAFLD). The non-invasive quantification of liver fat is now possible due to advances in imaging modalities. Emerging data suggest that high levels of liver fat and its temporal change, as measured by quantitative non-invasive methods, might be associated with NAFLD progression. Ultrasound-based modalities have moderate diagnostic accuracy for liver fat content and are suitable for screening. However, of the non-invasive imaging modalities, MRI-derived proton density fat fraction (MRI-PDFF) has the highest diagnostic accuracy and is used for trial enrolment and to evaluate therapeutic effects in early-phase clinical trials in nonalcoholic steatohepatitis (NASH). In patients with NAFLD without advanced fibrosis, high levels of liver fat are associated with rapid disease progression. Furthermore, changes on MRI-PDFF (≥30% decline relative to baseline) are associated with NAFLD activity score improvement and fibrosis regression. However, an inverse association exists between liver fat and complications of cirrhosis. Liver fat decreases as liver fibrosis progresses towards cirrhosis, and the clinical importance of quantitative measurements of liver fat differs by NAFLD status. As such, patients with NAFLD should be stratified by fibrosis severity to investigate the utility of quantitative measurements of liver fat for assessing NAFLD progression and prognosis.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34815553      PMCID: PMC9012520          DOI: 10.1038/s41574-021-00584-0

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   47.564


  112 in total

Review 1.  Liver biopsy.

Authors:  A A Bravo; S G Sheth; S Chopra
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

2.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  Stephen A Harrison; Mustafa R Bashir; Cynthia D Guy; Rong Zhou; Cynthia A Moylan; Juan P Frias; Naim Alkhouri; Meena B Bansal; Seth Baum; Brent A Neuschwander-Tetri; Rebecca Taub; Sam E Moussa
Journal:  Lancet       Date:  2019-11-11       Impact factor: 79.321

3.  Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Veeral Ajmera; Charlie C Park; Cyrielle Caussy; Seema Singh; Carolyn Hernandez; Ricki Bettencourt; Jonathan Hooker; Ethan Sy; Cynthia Behling; Ronghui Xu; Michael S Middleton; Mark A Valasek; Claire Faulkner; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2018-04-13       Impact factor: 22.682

4.  Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Authors:  Charlie C Park; Phirum Nguyen; Carolyn Hernandez; Ricki Bettencourt; Kimberly Ramirez; Lynda Fortney; Jonathan Hooker; Ethan Sy; Michael T Savides; Mosab H Alquiraish; Mark A Valasek; Emily Rizo; Lisa Richards; David Brenner; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2016-10-27       Impact factor: 22.682

5.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.

Authors:  Hashem B El-Serag; Thomas Tran; James E Everhart
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

6.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.

Authors:  Mazen Noureddin; Jessica Lam; Michael R Peterson; Michael Middleton; Gavin Hamilton; Thuy-Anh Le; Ricki Bettencourt; Chris Changchien; David A Brenner; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2013-10-17       Impact factor: 17.425

Review 7.  The role of PNPLA3 in health and disease.

Authors:  Piero Pingitore; Stefano Romeo
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-06-20       Impact factor: 4.698

8.  Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound.

Authors:  Alessandro de Moura Almeida; Helma Pinchemel Cotrim; Daniel Batista Valente Barbosa; Luciana Gordilho Matteoni de Athayde; Adimeia Souza Santos; Almir Galvão Vieira Bitencourt; Luiz Antonio Rodrigues de Freitas; Adriano Rios; Erivaldo Alves
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

Review 9.  Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.

Authors:  Jonathan G Stine; Nagambika Munaganuru; Abbey Barnard; Jennifer L Wang; Kellee Kaulback; Curtis K Argo; Siddarth Singh; Kathryn J Fowler; Claude B Sirlin; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2020-08-31       Impact factor: 11.382

10.  MRI-Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis.

Authors:  Rohit Loomba
Journal:  Hepatology       Date:  2021-03       Impact factor: 17.425

View more
  7 in total

1.  Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study.

Authors:  Aruhan Yang; Xiaoxue Zhu; Lei Zhang; Yingwen Zhang; Dezhi Zhang; Meishan Jin; Junqi Niu; Huimao Zhang; Yanhua Ding; Guoyue Lv
Journal:  Hepatol Int       Date:  2022-07-12       Impact factor: 9.029

2.  Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.

Authors:  Jinho Jung; Aiguo Han; Egbert Madamba; Ricki Bettencourt; Rohan R Loomba; Andrew S Boehringer; Michael P Andre; John W Erdman; William D O'Brien; Kathryn J Fowler; Claude B Sirlin; Rohit Loomba
Journal:  Radiology       Date:  2022-03-29       Impact factor: 29.146

3.  Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults.

Authors:  Ji-Hee Haam; Yun Kyong Lee; Eunkyung Suh; Young-Sang Kim
Journal:  Diagnostics (Basel)       Date:  2022-05-11

Review 4.  Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.

Authors:  Eirini Martinou; Marinos Pericleous; Irena Stefanova; Vasha Kaur; Angeliki M Angelidi
Journal:  Diagnostics (Basel)       Date:  2022-02-04

5.  Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.

Authors:  Anca Trifan; Ermina Stratina; Robert Nastasa; Adrian Rotaru; Remus Stafie; Sebastian Zenovia; Laura Huiban; Catalin Sfarti; Camelia Cojocariu; Tudor Cuciureanu; Cristina Muzica; Stefan Chiriac; Irina Girleanu; Ana-Maria Singeap; Carol Stanciu
Journal:  Diagnostics (Basel)       Date:  2022-07-20

6.  Feasibility of Ultrasound Attenuation Imaging for Assessing Pediatric Hepatic Steatosis.

Authors:  Kyungchul Song; Nak-Hoon Son; Dong Ryul Chang; Hyun Wook Chae; Hyun Joo Shin
Journal:  Biology (Basel)       Date:  2022-07-20

Review 7.  Advancing Liver Cancer Prevention for American Indian Populations in Arizona: An Integrative Review.

Authors:  Timian M Godfrey; Edgar A Villavicencio; Kimberly Barra; Priscilla R Sanderson; Kimberly Shea; Xiaoxiao Sun; David O Garcia
Journal:  Int J Environ Res Public Health       Date:  2022-03-10       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.